<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161028</url>
  </required_header>
  <id_info>
    <org_study_id>B2682-R</org_study_id>
    <nct_id>NCT03161028</nct_id>
  </id_info>
  <brief_title>Lipoic Acid for Progressive Multiple Sclerosis (MS)</brief_title>
  <acronym>LAPMS</acronym>
  <official_title>Lipoic Acid for the Treatment of Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if lipoic acid can preserve mobility and protect the
      brain in progressive forms of multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two-year study will determine if daily oral intake of lipoic acid will prove superior to
      placebo in reducing injury to the brain and maintaining mobility in progressive MS. Mobility
      will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as
      fall counts. Neuroprotection will be measured by the extent of brain volume loss seen on MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mobility: Timed 25 Foot Walk</measure>
    <time_frame>Change in Timed 25 Foot Walk from baseline to year 2</time_frame>
    <description>Change in Timed 25 Foot Walk from baseline to year 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mobility: 2-minute timed walk</measure>
    <time_frame>Change in 2-minute timed walk from baseline to year 2</time_frame>
    <description>Change in 2-minute timed walk from baseline to year 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility: Fall count</measure>
    <time_frame>Change in number of falls recorded from baseline to year 2</time_frame>
    <description>Change in number of falls recorded from baseline to year 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy by MRI</measure>
    <time_frame>% change brain volume from baseline to year 2</time_frame>
    <description>% change brain volume from baseline to year 2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety: laboratory safety monitoring, adverse event monitoring</measure>
    <time_frame>Adverse events and safety labs from baseline to year 2</time_frame>
    <description>Adverse events and safety labs from baseline to year 2</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Lipoic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>59 subjects receive oral lipoic acid 1200mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>59 subjects receive placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipoic acid</intervention_name>
    <description>1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.</description>
    <arm_group_label>Arm 1: Lipoic Acid</arm_group_label>
    <other_name>Alpha-lipoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of progressive MS as defined by the study

          -  Able to give informed consent and to adhere to study procedures.

          -  Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters
             without rest and use of bilateral aids (canes, crutches, walker) or better.

        Exclusion Criteria:

          -  A self-reported medical or neurological problem other than MS that is a cause of
             progressive or fluctuating gait dysfunction

          -  Unable to undergo MRI

          -  Unable to follow directions in English as standardized scales are not all validated in
             other languages.

          -  Current major disease or disorder other than MS (e.g., cancer, renal disease,
             end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may
             interfere with study procedures. Note: Stable abnormal laboratory values of no more
             than Grade 1 determined to not be of clinical significance to the primary treating
             physician for that condition may be permitted per local site investigator discretion.

          -  Pregnant or breast-feeding.

          -  Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications.

          -  Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to
             enrolment.

          -  IV or oral steroids in the 60 days prior to enrolment.

          -  Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months.

          -  Participation in the pilot LA in SPMS trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca I. Spain, MD MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Cameron</last_name>
    <phone>(503) 494-9548</phone>
    <email>camerola@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carin Waslo</last_name>
    <phone>(503) 418-2141</phone>
    <email>waslo@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Howard</last_name>
      <phone>205-934-1885</phone>
      <email>kdhoward@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>John Rinker II, MD</last_name>
      <email>jrinker@uabmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Jones</last_name>
      <phone>303-724-0797</phone>
      <email>haley.r.jones@CUANSCHUTZ.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center, Washington, DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carin Waslo</last_name>
      <phone>503-418-2141</phone>
      <email>waslo@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Cameron</last_name>
      <phone>(503) 494-9548</phone>
      <email>camerola@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca I. Spain, MD MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehana Hussain</last_name>
      <phone>214-648-7244</phone>
      <email>rehana.hussain@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Olaf Stuve, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaWanda Esquibel</last_name>
      <phone>801-587-3864</phone>
      <email>Lawanda.Esquibel@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mateo Paz Soldan, MD</last_name>
      <email>miguel.pazsoldan@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Kawai</last_name>
      <phone>323-442-5814</phone>
      <email>constance.kawai@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lawanda Esquibel</last_name>
      <phone>8015873864</phone>
      <email>lawanda.esquibel@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Azalone</last_name>
      <phone>802-847-6039</phone>
      <email>Emily.Azalone@uvmhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Solomon, MD</last_name>
      <phone>8028474589</phone>
      <email>Andrew.Solomon@uvmhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hirschler</last_name>
      <phone>206-277-5519</phone>
      <email>erin.hirschler@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jodie Haselkorn, MD</last_name>
      <email>Jodie.Haselkorn@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Johnson</last_name>
      <phone>206-320-7115</phone>
      <email>laura.johnson3@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Pavle Repovic, MD</last_name>
      <phone>2063202200</phone>
      <email>Pavle.Repovic@swedish.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Freedman</last_name>
      <phone>613-737-8104</phone>
      <phone_ext>2</phone_ext>
      <email>cfreedman@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mark Freedman, MD</last_name>
      <email>mfreedman@toh.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>gait</keyword>
  <keyword>neuroprotective agents</keyword>
  <keyword>thioctic acid</keyword>
  <keyword>alpha-lipoic acid</keyword>
  <keyword>mobility</keyword>
  <keyword>chronic progressive multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

